Home NTLA
43.85
  Price1.43%   +0.62
(After Hours: 44.21 +0.36 +0.82% )
loading

Intellia Therapeutics (NTLA) Latest News

Feb-06-23 09:55AM Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to TradeZacks Investment Research
05:55AM 3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%The Motley Fool
Feb-03-23 02:43AM 4 Biotech Stocks Set to Outpace Q4 Earnings EstimatesZacks Investment Research
Feb-01-23 01:03AM Analyst Initiates Coverage On This Peer Lagging Gene-Editing StockBenzinga
10:00AM Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023Benzinga
Jan-27-23 01:28AM Tracking Cathie Wood's ARK Invest 13F Portfolio - Q4 2022 UpdateSeeking Alpha
Jan-24-23 11:45AM Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe Motley Fool
11:00AM Expert Ratings for Intellia TherapeuticsBenzinga
Jan-24-23 10:01AM Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023Benzinga
Jan-19-23 10:01AM Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023Benzinga
Jan-13-23 09:55AM Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?Zacks Investment Research
Jan-12-23 12:15PM Prime Medicine 'Crispr 3.0' Vs. Crispr TherapeuticsSeeking Alpha
Jan-11-23 07:30AM Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary AngioedemaGlobeNewswire Inc.
Jan-05-23 07:30AM Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones GlobeNewswire Inc.
Dec-30-22 10:07AM 1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)The Motley Fool
Dec-02-22 07:59AM Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For FridayBenzinga
07:06AM Analyst Ratings for Intellia TherapeuticsBenzinga
Nov-30-22 09:29AM Intellia Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire Inc.
04:37AM Intellia Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire Inc.
Nov-15-22 06:53AM Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%Benzinga
Nov-12-22 04:30AM Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific MeetingGlobeNewswire Inc.
Nov-05-22 04:00AM Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022GlobeNewswire Inc.
Nov-03-22 01:27AM Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/YZacks Investment Research
07:30AM Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewswire Inc.
Nov-02-22 12:51PM CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag EstimatesZacks Investment Research
12:30PM Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 GuidanceZacks Investment Research
Nov-01-22 10:27AM Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022Benzinga
Oct-31-22 07:30AM Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific MeetingGlobeNewswire Inc.
Oct-27-22 10:03AM Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research
07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company UpdatesGlobeNewswire Inc.
Oct-24-22 05:21AM Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
Oct-19-22 09:23AM 3 Cathie Wood Stocks to Buy and Hold for 10 YearsThe Motley Fool
03:10AM Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 UpdateSeeking Alpha
Oct-13-22 06:10AM Moderna (MRNA) Soars 8.3%: Is Further Upside Left in the Stock?Zacks Investment Research
Oct-11-22 10:06AM Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022Benzinga
09:18AM 7 Analysts Have This to Say About Intellia TherapeuticsBenzinga
Sep-22-22 05:49AM Cathie Wood Goes Shopping for Biotech: 3 Stocks She Just BoughtThe Motley Fool
Sep-21-22 10:04AM Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022Benzinga
Sep-20-22 05:55AM Cathie Wood Is Loading Up on These 3 Stocks: Should You?The Motley Fool
Sep-19-22 05:35AM "The Era of the Gene-Edited Human Is Here"The Motley Fool
12:15PM Intellia (NTLA) Reports Positive Results for CRISPR CandidatesZacks Investment Research
Sep-19-22 12:06PM SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To KnowBenzinga
10:15AM 2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 YearsThe Motley Fool
Sep-19-22 10:02AM What 4 Analyst Ratings Have To Say About Intellia TherapeuticsBenzinga
07:19AM This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedExBenzinga
Sep-16-22 07:15AM Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisGlobeNewswire Inc.
07:00AM Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)GlobeNewswire Inc.
Sep-01-22 10:33AM Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022Benzinga
09:18AM Expert Ratings for Intellia TherapeuticsBenzinga
Sep-01-22 09:13AM Where Intellia Therapeutics Stands With AnalystsBenzinga
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Cap:    |  Volume (24h):